This company has been acquired
Resumen acción STSA
Satsuma Pharmaceuticals, Inc., a development-stage biopharmaceutical company, develops novel therapeutic products for the acute treatment of migraines.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Recompensas
Análisis de riesgos
+ 2 riesgos adicionales
Competidores de Satsuma Pharmaceuticals, Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.10 |
| 52 Week High | US$8.08 |
| 52 Week Low | US$0.59 |
| Beta | 0.10 |
| 1 Month Change | 3.77% |
| 3 Month Change | 19.59% |
| 1 Year Change | -67.46% |
| 3 Year Change | -95.92% |
| 5 Year Change | n/a |
| Change since IPO | -93.49% |
Noticias y actualizaciones recientes
Recent updates
Can Satsuma Pharmaceuticals (NASDAQ:STSA) Afford To Invest In Growth?
Feb 15
Will Satsuma Pharmaceuticals (NASDAQ:STSA) Spend Its Cash Wisely?
Sep 02Here's Why We're Watching Satsuma Pharmaceuticals' (NASDAQ:STSA) Cash Burn Situation
May 13Satsuma Pharmaceuticals: Sizing Up This One Trick Pony
Nov 07Satsuma shares surge on data from early-stage STS101 trial
Jun 16Do Institutions Own Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) Shares?
Jan 26Rentabilidad de los accionistas
| STSA | US Pharmaceuticals | Mercado US | |
|---|---|---|---|
| 7D | 4.8% | -3.3% | -3.1% |
| 1Y | -67.5% | 11.3% | 20.9% |
Rentabilidad vs. Industria: STSA underperformed the US Pharmaceuticals industry which returned 2% over the past year.
Rentabilidad vs. Mercado: STSA underperformed the US Market which returned 5% over the past year.
Volatilidad de los precios
| STSA volatility | |
|---|---|
| STSA Average Weekly Movement | 20.0% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: STSA's share price has been volatile over the past 3 months.
Volatilidad a lo largo del tiempo: STSA's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of US stocks.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2016 | 25 | John Kollins | www.satsumarx.com |
Resumen de fundamentos de Satsuma Pharmaceuticals, Inc.
| Estadísticas fundamentales de STSA | |
|---|---|
| Capitalización bursátil | US$36.47m |
| Beneficios(TTM) | -US$64.83m |
| Ingresos (TTM) | n/a |
0.0x
Ratio precio-ventas (PS)-0.6x
Ratio precio-beneficio (PE)¿Está STSA sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de STSA | |
|---|---|
| Ingresos | US$0 |
| Coste de los ingresos | US$0 |
| Beneficio bruto | US$0 |
| Otros gastos | US$64.83m |
| Beneficios | -US$64.83m |
Últimos beneficios comunicados
Mar 31, 2023
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -1.96 |
| Margen bruto | 0.00% |
| Margen de beneficio neto | 0.00% |
| Ratio deuda/patrimonio | 0% |
¿Cómo se ha desempeñado STSA a largo plazo?
Ver rendimiento histórico y comparativa